Quantum signs agreement with a global pharmaceutical research organization

Quantum BioPharma announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND application package for Lucid-21-302, Lucid-MS, with the US FDA. A successful IND application will allow Quantum Biopharma to move forward with a Phase 2 trial of Lucid-21-302 in people with multiple sclerosis, MS. Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of MS. It is a patented New Chemical Entity that has been shown in preclinical models to prevent demyelination, a known cause of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers.